Azetidinone derivatives for the treatment of HCMV infections

Details Azetidinone derivatives for the treatment of HCMV infections Azetidinone derivatives for the treatment of HCMV infections

1998-10-06

2001-06-05

Berch, Mark (Department: 1611)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C540S200000

Reexamination Certificate

active

06242439

ABSTRACT:

FIELD OF THE INVENTION
This invention relates to azetidinone derivatives having activity against herpes infections. More specifically, the invention relates to azetidin-2-one derivatives exhibiting antiherpes activity, to pharmaceutical compositions comprising the derivatives, and methods of using the derivatives to inhibit the replication of herpes virus and to treat herpes infections.
BACKGROUND OF THE INVENTION
Herpes viruses inflict a wide range of diseases against humans and animals. For instance, herpes simplex viruses, types 1 and 2 (HSV-1 and HSV-2), are responsible for cold sores and genital lesions, respectively; varicella zoster virus (VZV) causes chicken pox and shingles; and the human cytomegalovirus (HCMV) is a leading cause of opportunistic infections in immunosuppressed individuals.
Over the past two decades, a class of compounds known as the purine and pyrimidine nucleoside analogs has received the most attention by investigators in the search for new therapeutic agents for treatment of herpes virus infections. As a result, several nucleoside analogs have been developed as antiviral agents. The most successful to date is acyclovir which is the agent of choice for treating genital HSV infections. Another nucleoside analog, ganciclovir, has been used with some success in treating HCMV infections.
Nevertheless, in spite of some significant advances, the need for effective, safe therapeutic agents for treating herpes viral infections continues to exist. For a review of current therapeutic agents in this area, see R. E. Boeheme et al., Annual Reports in Medicinal Chemistry, 1995, 30, 139.
Azetidin-2-one derivatives have been reported in the literature as having a variety of biological activities; mainly antibacterial, antiinflammatory, antidegenerative, etc. However, azetidin-2-one derivatives have not been reported to be antiviral agents against herpes viruses.
The following references disclose azetidin-2-ones having biological activity:
S. K. Shah et al., European patent application 0,199,630, Oct. 29, 1986,
S. K. Shah et al., European patent application 0,377,549, Oct. 18, 1989,
P. L. Durette and M. Maccoss, U.S. Pat. No. 5,100,880, Mar. 31, 1992,
P. L. Durette and M. Maccoss, U.S. Pat. No. 5,104,862, Apr. 14, 1992,
W. K. Hagmann et al.,
Bioorg. Med. Chem. Lett.
1992, 2, 681,
W. K. Hagmann et al.,
J. Med. Chem.
1993, 36, 771, J. B. Doherty et al., U.S. Pat. No. 5,229,381, issued Jul. 20, 1993,
S. K. Shah et al.,
Bioorg. Med. Chem. Lett.
1993, 3, 2295,
G. Crawley, PCT patent WO 95/02579, published Jan. 26, 1995,
P. E. Finke et al.,
J. Med. Chem.
1995, 38, 2449, and K. Kobayashi et al., Japanese patent application 07242624, published Sep. 19, 1995;
Chem. Abstr.
1996, 124, 29520.
SUMMARY OF THE INVENTION
The present application discloses a group of azetidin-2-one derivatives particularly active against cytomegalovirus. This activity coupled with a wide margin of safety, renders these derivatives desirable agents for combating herpes infections.
The present azetidin-2-one derivatives are distinguished from the prior art compounds in that they possess different chemical structures and biological activities.
The azetidin-2-one derivatives are represented by formula 1:
wherein R
1
is hydrogen, methyl, ethyl, methoxy or methylthio;
R
2
and R
3
each independently is hydrogen or lower alkyl;
R
4
is hydrogen, lower alkyl, methoxy, ethoxy or benzyloxy;
R
5
is lower alkyl, lower cycloalkyl, (CH
2
)
m
C(O)OR
6
wherein m is the integer 1 or 2 and R
6
is lower alkyl or phenyl(lower alkyl);
phenyl, phenyl monosubstituted, disubstituted or trisubstituted with a substituent selected independently from the group consisting of lower alkyl, lower alkoxy, lower alkylthio, halo, hydroxy and amino; phenyl(lower alkyl), phenyl(lower alkyl) monosubstituted or disubstituted on the phenyl portion thereof with a substituent selected independently from the group consisting of lower alkyl, lower alkoxy, lower alkylthio, halo, hydroxy, nitro, amino, lower alkylamino, di(lower alkyl)amino, lower alkyl-C(O)NH, di(lower alkyl)aminocarbonyl, cyano, trifluoromethyl, (trifluoromethyl)thio, (trifluoromethyl)sulfinyl, (trifluoromethyl)sulfonyl and C(O)OR
7
wherein R
7
is lower alkyl or phenyl(lower alkyl);
Het or Het(lower alkyl) wherein Het represents an unsubstituted, monosubstituted or disubstituted five or six membered, monovalent heterocyclic ring containing one or two heteroatoms selected from the group consisting of N, O or S, wherein each substituent is selected independently from the group consisting of lower alkyl, lower alkoxy, halo and hydroxy;
5-(benzo[1,3]dioxolyl)methyl, (1(R)-1-naphthalenyl)ethyl, 2-benzothiazolyl or 2-thiazolo[4,5-b]pyridinyl; or
R
4
and R
5
together with the nitrogen atom to which they are attached form a piperidino, morpholino, thiomorpholino, piperazino, N-methylpiperazino, 1-(3,4-dihydro-1H-isoquinolinyl) or 2-(3,4-dihydro-1H-isoquinolinyl) or a pyrrolidino ring optionally substituted with benzyloxycarbonyl or with phenyl said phenyl ring optionally mono- or di-substituted with a substituent selected independently from the group consisting of lower alkyl, lower alkoxy, lower alkylthio, halo, hydroxy, nitro, amino, lower alkylamino, di(lower alkyl)amino, lower alkyl-C(O)NH, di(lower alkyl)aminocarbonyl, cyano, trifluoromethyl, (trifluoromethyl)thio, (trifluoromethyl)sulfinyl, (trifluoromethyl)sulfonyl and C(O)OR
7
wherein R
7
is lower alkyl or (lower alkyl)phenyl; and
Z is lower alkyl, phenyl, phenyl monosubstituted or disubstituted with a substituent selected independently from lower alkyl, lower alkoxy, halo, hydroxy and amino; phenylmethyl, phenylmethyl mono-substituted or disubstituted on the phenyl portion thereof with a substituent selected from the group consisting of lower alkyl, lower alkoxy, halo, hydroxy and amino; or (CH
2
)
p
-(Het) wherein p is the integer 0 or 1 and Het is as defined herein; with the proviso that when Z is (CH
2
)
p
-(Het) as defined herein then R
2
and R
3
each is hydrogen;
or a therapeutically acceptable acid addition salt thereof.
A preferred group of compounds is represented by formula 1 wherein R
1
, R
2
and R
3
are as defined hereinabove;
R
4
is hydrogen or lower alkyl;
R
5
is lower alkyl, lower cycloalkyl, CH
2
C(O)OR
6
wherein R
6
is methyl, ethyl or phenylmethyl; phenyl, phenyl monosubstituted, disubstituted or trisubstituted with a substituent selected independently from the group consisting of lower alkyl, lower alkoxy, lower alkylthio, halo, hydroxy and amino; phenyl(lower alkyl), phenyl(lower alkyl) monosubstituted or disubstituted on the phenyl portion thereof with a substituent selected independently from the group consisting of lower alkyl, lower alkoxy, lower alkylthio, halo, hydroxy, nitro, amino, lower alkylamino, di(lower alkyl)amino, lower alkyl-C(O)NH, di(lower alkyl)aminocarbonyl, cyano, trifluoromethyl, (trifluoromethyl)thio, (trifluoromethyl)sulfinyl, (trifluoromethyl)sulfonyl and C(O)OR
7
wherein R
7
is methyl, ethyl or phenylmethyl; Het or Het(lower alkyl) wherein Het is 2-furyl, 2-methyl-3-furyl, 2-thienyl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 3-methyl-2-pyrrolyl, 2-thiazolyl, 4-thiazolyl, 2-isoxazolyl, 2-pyrimidinyl, 4-methyl-2-pyrimidinyl, 4,6-dimethyl-2-pyrimidinyl, 4-pyrimidinyl, 2,6-dimethyl-2-pyrimidinyl, 4-methyltetrazolyl, 2-benzothiazolyl or 2-thiazolo[4,5-b]pyridinyl; (5-benzo[1,3]dioxolyl)methyl, 1(R)-(1-naphthalenyl)ethyl; or
R
4
and R
5
together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino, morpholino, N-methylpiperazino, 1-(3,4-dihydro-1H-isoquinolinyl) or 2-(3,4-dihydro-1H-isoquinolinyl);
and Z is as defined hereinabove.
A more preferred group of compounds is represented by formula 1 wherein R
1
is hydrogen, methyl, ethyl, methoxy or methylthio;
R
2
and R
3
each independently is hydrogen, or methyl;
R
4
is hydrogen, methyl, or ethyl;
R
5
is methyl, ethyl, 1-methylethyl, cyclobutyl, cyclopentyl, cyclohexyl, CH
2
C(O)OR
6
wherein R
6
is methyl or phenylmethyl; phenyl, 4-fluo

Affiliated with

Also associated with

Rating

Azetidinone derivatives for the treatment of HCMV infections does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Azetidinone derivatives for the treatment of HCMV infections, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Azetidinone derivatives for the treatment of HCMV infections will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2546233